LIQUIDITY (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		12 Months Ended
	Jan. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023
Accumulated deficit		$ (275,509)		$ (260,985)
Net loss		(14,524)	$ (9,831)	(51,800)
Net cash used in operating activities		(10,585)	$ (7,589)	(44,500)
Cash and cash equivalents		8,057		16,036
Short-term investments		90,673		85,860
Long-term investments		8,144		16,470
Total liabilities		9,435		7,549
Current liabilities		7,195		$ 5,200
XOMA (US) LLC | Phase 3 Clinical Trial RZ 358 | Xoma License Agreement | Scenario, Upon First Dosing Of The First Patient [Member]
Milestone closing payment	$ 5,000	5,000
XOMA (US) LLC | Phase 3 Clinical Trial RZ 358 | Xoma License Agreement | Scenario, Upon Dosing Of The Last Patient [Member]
Milestone closing payment		$ 5,000